Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX followed by chemo-IMRT in locally advanced unresectable pancreatic cancer
2013-002074-46Phase 2Terminated
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan and fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: objective response rate and unacceptable toxicity rate. Started Jun 2013; status: terminated.
02
Drugs
oxaliplatinirinotecanfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-002074-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002074-46.